New drug combo aims to outsmart lung Cancer's immune evasion
NCT ID NCT05782361
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests two drugs, tepotinib and pembrolizumab, together in 19 people with advanced non-small cell lung cancer. Tepotinib targets a specific gene change (MET) that can help cancer grow, while pembrolizumab boosts the immune system. The goal is to see if this combination can shrink tumors in patients whose cancers don't respond to immunotherapy alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tepotinib and pembrolizumab
What this could lead to
If it works, this combination could offer a new treatment option for non-small cell lung cancer patients who don't respond to immunotherapy alone.
What could go wrong
This is a very early phase 1 trial with only 19 participants, so results may not apply widely. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
DDU, Royal Marsden Hospital NHS Foundation Trust
Sutton, Surrey, SM2 5PT, United Kingdom
-
Lung Unit, Royal Marsden Hospital NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
University College London Hospitals NHS Foundation Trust
London, NW1 2BU, United Kingdom